SP-2577 Granted Fast Track Designation by the FDA for Patients with Ewing Sarcoma

The drug is currently the subject of an ongoing phase I/II clinical study for the treatment of patients with Ewing sarcoma who have relapsed or are refractory to standard-of-care therapy.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news